Inside Diagnostics ESP Lung EQA Scheme 2018 invitation: ensuring optimal accuracy and proficiency in NSCLC targeted therapy biomarker testing in all countries


Optimal accuracy and proficiency in biomarker testing is crucial for effective targeted therapy selection for non-small cell lung cancer (NSCLC) patients. To ensure and promote quality biomarker testing, the European Society of Pathology Quality Assurance (ESPQA) Foundation and the KU Leuven External Quality Assessment (EQA) scheme coordination centre invite you to participate in the ESP Lung External Quality Assessment Scheme 2018. The program, taking place between March and December 2018, will provide quality assessments of oncology targeted therapy biomarker testing methodologies performed in participating laboratories, to validate and improve their diagnostic practice.

This program consists of the following schemes and sub schemes:

  1. Molecular NSCLC scheme (resection specimens used)
    • Mandatory EGFR analysis
    • Optional BRAF testing
    • Optional KRAS testing
  2. ALK scheme (resections used for IHC/FISH and additionally digital cases for FISH)
    • IHC technical assessment
    • FISH digital image evaluation
    • Resections used
  3. ROS1 scheme (same as above)
    • IHC technical assessment
    • FISH digital image evaluation
  4. PD-L1 EQA scheme (TMA resections and digital cases used)
  5. c-MET pilot EQA scheme (resections used, scheme organisation to be confirmed)




Sample distribution will occur in three rounds in March, June and October 2018. Participating laboratories will need to submit reports on the methods and results of biomarker testing on received EQA samples using their routine protocols. Technical assessments (IHC) will consist of a pathology review and microscopic assessment. Results will be evaluated based on consensus agreement of NSCLC-relevant publications and ISO standards. EQA scheme results for rounds 1−3 will be released in December 2018.

ESP EQA schemes are accredited by BELAC conform the ISO 17043, and laboratories performing adequately in the EQA round will be published on the ESP website.

Fees range from 200€−550€ depending on the scheme registered for.
Laboratories in all countries can register until February 1st 2018.
Registration is available here:
Individual sub scheme registration is also possible.


Rudy Hovelinck
Diagnostics Manager at AstraZeneca


NS ID BE 1449-RD01/2018

Other Inside Diagnostic Articles

About the Author

Rudy Hovelinck

Diagnostics Manager AstraZeneca

M. +32 (0) 476 22 58

Rudy Hovelinck obtained a scientific degree first in biochemistry at Ghent University and later in Molecular Biology at the ULB. Initially exploring the academic world in diverse fields as genetics, protein chemistry and virology, he soon realised that bridging scientific knowledge to the medical world was a more meaningful way of spending his professional life. This journey started in the field of pathology biomarker testing, introducing HER2 IHC and ISH testing for patient therapy selection and continued in the field of molecular oncology. Today at AstraZeneca he works as a diagnostics manager. In this role he is passionately contributing to the successful introduction of novel biomarkers and support current testing strategies for patient selection. In his own time he enjoys travelling with his family exploring the world and spending time close to nature. Specialties: Oncology, Anatomic Pathology, Biomarker Development, Medical Devices.